UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

The Lancet (British edition), 2021-03, Vol.397 (10277), p.892-901

2021

Volltextzugriff (PDF)

Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review

Haematologica (Roma), 2020-07, Vol.105 (7), p.1914-1924

2020

Volltextzugriff (PDF)

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy

Haematologica (Roma), 2019-02, Vol.104 (2), p.e68-e71

2019

Volltextzugriff (PDF)

How I manage mantle cell lymphoma: indolent versus aggressive disease

British journal of haematology, 2023-04, Vol.201 (2), p.185-198

2023

Volltextzugriff (PDF)

The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives

Cancers, 2023-05, Vol.15 (9), p.2596

2023

Volltextzugriff (PDF)

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study

Blood, 2019-01, Vol.133 (4), p.299-305

2019

Volltextzugriff (PDF)

Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia

Blood, 2021-05, Vol.137 (20), p.2800-2816

2021

Volltextzugriff (PDF)

Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison

Haematologica (Roma), 2024-06

2024

Volltextzugriff (PDF)

Immune checkpoint inhibition in lymphoid disease

British journal of haematology, 2015-08, Vol.170 (3), p.291-304

2015

Volltextzugriff (PDF)

Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients

PloS one, 2020-02, Vol.15 (2), p.e0229469-e0229469

2020

Volltextzugriff (PDF)

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib

Haematologica (Roma), 2023-05, Vol.108 (5), p.1429-1435

2023

Volltextzugriff (PDF)

Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients

PloS one, 2022-01, Vol.17 (1), p.e0262388-e0262388

2022

Volltextzugriff (PDF)

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series

Hematology (Luxembourg), 2022-12, Vol.27 (1), p.204-207

2022

Volltextzugriff (PDF)

The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease

BMC cancer, 2019-05, Vol.19 (1), p.471-12, Article 471

2019

Volltextzugriff (PDF)

Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation

Haematologica (Roma), 2023-03, Vol.108 (3), p.785-796

2023

Volltextzugriff (PDF)

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care

Haematologica (Roma), 2020-09, Vol.105 (9), p.e474-479

2020

Volltextzugriff (PDF)

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study

Haematologica (Roma), 2018-07, Vol.103 (7), p.1209-1217

2018

Volltextzugriff (PDF)

Richter transformation-is there light at the end of this tunnel?

Hematology, 2023-12, Vol.2023 (1), p.427-432

Eyre, Toby A

2023

Volltextzugriff (PDF)

Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review

Blood advances, 2021-05, Vol.5 (9), p.2426-2437

2021

Volltextzugriff (PDF)

A phase II trial of AZD1152 in relapsed/refractory diffuse large B‐cell lymphoma

British journal of haematology, 2015-09, Vol.170 (6), p.886-890

2015

Volltextzugriff (PDF)

The use of frailty assessments in treating older adults with aggressive lymphomas

British journal of haematology, 2021-08, Vol.194 (4), p.677-685

2021

Volltextzugriff (PDF)

A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma

BMC cancer, 2021-07, Vol.21 (1), p.1-851, Article 851

2021

Volltextzugriff (PDF)

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Blood advances, 2020-08, Vol.4 (16), p.3977-3989

2020

Volltextzugriff (PDF)

1 – 25 von 271

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(261)
Mit Volltextzugriff
(231)

Publikationsform

Sprache

Englisch
(271)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(137)
Life Sciences & Biomedicine
(135)
Hematology
(116)
Humans
(104)
Aged
(38)
Male
(37)
Female
(36)
Adult
(34)
Lymphoma
(34)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(31)
Middle Aged
(29)
Oncology
(27)
Treatment Outcome
(24)
Retrospective Studies
(23)
Aged, 80 And Over
(22)
Patients
(21)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(19)
Chemotherapy
(19)
Clinical Trials
(19)
Chronic Lymphocytic Leukemia
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in the rituximab era: a systematic review

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy

How I manage mantle cell lymphoma: indolent versus aggressive disease

The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives

Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study

Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia

Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison

Immune checkpoint inhibition in lymphoid disease

Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib

International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma

Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series

The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease

Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study

Richter transformation-is there light at the end of this tunnel?

Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review

A phase II trial of AZD1152 in relapsed/refractory diffuse large B‐cell lymphoma

The use of frailty assessments in treating older adults with aggressive lymphomas

A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Suchergebnisse filtern